Please login to the form below

basal cell carcinoma

This page shows the latest basal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s latecomer PD-1 gets date for FDA verdict

The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... after basal cell carcinoma (BCC) and the deadliest

Latest news

Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

The data in cutaneous squamous cell carcinoma (CSCC), the second most common form of skin cancer, comes from a single-arm, open-label trial involving 82 patients and showed an overall ... The company plans to have pivotal trials ongoing in first-line
Pfizer's SMO inhibitor boosts survival in blood cancer trial

basal cell carcinoma in patients not suitable for surgery or radiotherapy. ... in a phase I/II trial in small cell lung cancer (SCLC) patients.
Rare disease therapies head the ‘class of 2015’

A product in a new class of cancer therapies that harness the cell-killing power of viruses also debuted in 2015 in the form of Amgen's Imlygic (talimogene laherparepvec), the ... Actelion. USA. sonidegib. Odomzo. basal cell carcinoma. SMO receptor
EU green light for Novartis' skin cancer therapy

EU green light for Novartis' skin cancer therapy. Swiss firm’ s basal cell carcinoma treatment can now be launched across Europe. ... Odomzo (sonidegib) is used to treat locally-advanced basal cell carcinoma - the most common form of skin cancer - in
FDA approves four new medicines across multiple areas

Skin cancer. Meanwhile, Novartis' Odomzo (sonidegib) has been approved for locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or who are not candidates for surgery

More from news
Approximately 5 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Deal Watch December 2016

295. Novartis (Switzerland). Sun Pharma (India). Asset acquisition. Odomzo (sonidegib; hedgehog pathway inhibitor), approved in basal cell carcinoma. ... Abzena's technology is used to humanise and de-immunise antibodies by avoiding CD4+ T-cell epitopes.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Chris Bowden joins Agios

During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.
Curis looks to MedImmune and Takeda for new hires

Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Delivery Manager/ Head of Delivery – Executive Search: Neg

Client Services Director – Healthcare Advertising - London: Neg

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Editorial Team Leader, Medical Communications: Excellent package

Home based, Chief Medical Writer, Medical Communications: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Healthcare PR Director: £100, 000 – £120, 000 benefits

Client Services Director - Med Comms: Great salary and bebefits

Business Unit Head, Medical Communications, London: Excellent package

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Editorial Director – Medical Education (MedComms): Neg

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Home based, Senior Medical Writer, Medical Communications: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....